Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2011-12-01 Director's Dealing
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
MAIN DOCUMENT DESCRIPTION
Director's Dealing
2011-12-01 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an event where the FDA issued a complete response letter (CRL) regarding a drug application, which is a significant regulatory event. The document includes a press release as an exhibit. The length is 3238 characters, which is relatively short and mainly announces an event rather than providing detailed financial data or comprehensive reports. This fits the category of Regulatory Filings (RNS), which is a fallback for miscellaneous filings that do not fit other specific categories and often include current event disclosures like FDA responses and press releases. It is not an Annual Report, Earnings Release, or any other detailed financial or management report. Therefore, the correct classification is Regulatory Filings (RNS).
2011-11-14 English
AMENDED 10-Q
Interim / Quarterly Report Q1 2011
2011-11-09 English
FORM 10-Q
Interim / Quarterly Report Q1 2012
2011-11-08 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and states that the company issued a press release announcing its first quarter fiscal year 2012 results. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 2659 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and announces or furnishes a press release with results, it should be classified as an Earnings Release (ER) rather than an Interim Report (IR) or Annual Report (10-K). Therefore, the appropriate classification is Earnings Release (ER).
2011-11-07 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(3) and (c), which is a regulatory filing related to securities offerings. It provides detailed information about shares of common stock being offered, including selling security holders and warrants. This type of document is not a full financial report, earnings release, or management discussion, but rather a supplement to a prospectus related to capital raising activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not merely an announcement but a substantive supplement to a prospectus.
2011-11-03 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.